Sanara MedTech/$SMTI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sanara MedTech
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
Ticker
$SMTI
Sector
Primary listing
Employees
141
Headquarters
Website
Sanara MedTech Metrics
BasicAdvanced
$302M
-
-$1.16
1.19
-
Price and volume
Market cap
$302M
Beta
1.19
52-week high
$38.68
52-week low
$23.53
Average daily volume
36K
Financial strength
Current ratio
2.263
Quick ratio
1.947
Long term debt to equity
127.905
Total debt to equity
128.422
Interest coverage (TTM)
-0.65%
Profitability
EBITDA (TTM)
0.996
Gross margin (TTM)
91.76%
Net profit margin (TTM)
-10.22%
Operating margin (TTM)
-3.55%
Revenue per employee (TTM)
$690,000
Management effectiveness
Return on assets (TTM)
-2.50%
Return on equity (TTM)
-26.38%
Valuation
Price to revenue (TTM)
2.989
Price to book
8.54
Price to tangible book (TTM)
-32.88
Price to free cash flow (TTM)
8,196.959
Free cash flow yield (TTM)
0.01%
Free cash flow per share (TTM)
0.004
Growth
Revenue change (TTM)
34.29%
Earnings per share change (TTM)
48.58%
3-year revenue growth (CAGR)
47.44%
10-year revenue growth (CAGR)
40.85%
3-year earnings per share growth (CAGR)
3.57%
10-year earnings per share growth (CAGR)
-5.14%
What the Analysts think about Sanara MedTech
Analyst ratings (Buy, Hold, Sell) for Sanara MedTech stock.
Bulls say / Bears say
Consistent revenue momentum: Net revenue rose 26% to $23.4 million in Q1 2025 and 28% to $25.8 million in Q2 2025, fueled by strong demand for CellerateRX Surgical collagen and bone fusion products (GlobeNewswire Q1, GlobeNewswire Q2).
Margin expansion: Gross margin improved to 93% in Q2 2025 from 90% a year earlier, reflecting operational leverage from the high-margin soft tissue repair business (GlobeNewswire).
Strategic pipeline enhancement: On January 21, 2025, Sanara signed an exclusive license and distribution agreement and invested in Biomimetic Innovations Ltd for its OsStic Synthetic Injectable Structural Bio-Adhesive Bone Void Filler, targeting a market of over 100,000 annual U.S. procedures (GlobeNewswire).
Continued unprofitability: Sanara posted a net loss of $5.5 million in the first half of 2025, compared to a $5.3 million loss in the same period of 2024. This shows little movement toward break-even, even with robust revenue gains (GlobeNewswire).
Rising leverage: Long-term debt increased to $44.2 million as of June 30, 2025, up from $30.7 million at the end of 2024, raising interest expenses and financial risk (GlobeNewswire).
Underperforming THP segment: The Tissue Health Plus subsidiary's net loss widened to $5.4 million in H1 2025 from $2.6 million in H1 2024, highlighting ongoing challenges in commercializing its wound care platform despite launching pilot programs (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 27 Aug 2025.
Sanara MedTech Financial Performance
Revenues and expenses
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sanara MedTech stock?
Sanara MedTech (SMTI) has a market cap of $302M as of September 14, 2025.
What is the P/E ratio for Sanara MedTech stock?
The price to earnings (P/E) ratio for Sanara MedTech (SMTI) stock is 0 as of September 14, 2025.
Does Sanara MedTech stock pay dividends?
No, Sanara MedTech (SMTI) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next Sanara MedTech dividend payment date?
Sanara MedTech (SMTI) stock does not pay dividends to its shareholders.
What is the beta indicator for Sanara MedTech?
Sanara MedTech (SMTI) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.